- Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.
- Ginkgo will use its Protein Production Services and generative AI platform to deliver best-in-class candidate strains to Vivici.
- Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialised nutrition companies, to bring planet-friendly nutrition to consumers.
DELFT, Netherlands and BOSTON, Nov. 27, 2023 /PRNewswire/ -- Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimisation and performance, to develop and commercialise a next generation of functional alternative protein.
Alternative Dairy Protein Production with Precision Fermentation
Vivici, a startup company founded by DSM Venturing (now part of dsm-firmenich) and Fonterra, is on a mission to meet the world's growing need for sustainable, nutritious and great tasting proteins. Recognizing the need for alternatives to traditional animal agriculture, Vivici employs precision fermentation techniques to produce animal-free dairy proteins with microorganisms. This innovative approach not only supplements the existing animal protein supply, but also paves the way for a more sustainable food system in the future.
Ginkgo's Tech Solution: Strain Development at Foundry Scale
Ginkgo plans to support Vivici by delivering optimized strains for dairy protein production via precision fermentation. Ginkgo intends to design and build an integrated library, screen for strains with the best protein expression, validate and grow the most promising hits, and then transfer the top performing strains to Vivici for evaluation. The aim is for these strains to enable optimal protein expression, superior functionality, and commercial-level titers.
"We are thrilled to collaborate with Ginkgo. Ginkgo's scale and AI-driven approach to designing strains for protein expression is a differentiated offering. We are confident in Ginkgo's capabilities to provide efficient, scalable strains that can support Vivici's speed to market," said Stephan van ...